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The  genus  Erythrina,  Fabaceae,  is widely  distributed  in  tropical  and  subtropical  regions.  Their  ﬂowers,
fruits,  seeds  and  bark  are  frequently  used  in folk  medicine  for its  effects  on  the  central  nervous  system
such  as  anticonvulsant,  antidepressant,  analgesic,  sedative,  and  hypnotic  effects.  Erythraline  has  beeneywords:
abaceae
rythraline
YP450
rug metabolism
reported  as  one  of  the  active  compounds  from  Erythrina,  but until  now  there  are  no pharmacokinetics
data about  this  compound  and  only  few results  showing  a  putative  metabolism  were  reported.  To  improve
the  information  about  erythraline  metabolism,  this  article  reports  and discusses,  for  the ﬁrst  time,  the
in  vitro  metabolism  biotransformation  of erythraline  by  cytochrome  P450  enzymes.
©  2015  Sociedade  Brasileira  de  Farmacognosia.  Published  by Elsevier  Editora  Ltda.  All  rights  reserved.icrosomal model
ntroduction
Natural products have historically played a major role in the dis-
overy and development of a diverse array of therapeutics (Kurita
nd Linington, 2015). They represent a rich source of chemical
iversity, between 25 and 50% of approved drugs are originated
rom natural products. However, discovery, isolation, and develop-
ent of natural products as pharmaceutical drugs are exceptionally
hallenging, requiring a multi-disciplinary approach to unlock their
otential (Ogbourne and Parsons, 2014).
The genus Erythrina, Fabaceae, is widely distributed in tropical
nd subtropical regions (Arita et al., 2014). Erythrina verna Vell. is a
eciduous tree found mainly in Brazilian cerrados and other trop-
cal regions. Its ﬂowers, fruits, seeds and bark are frequently used
n folk medicine due to their effects on the central nervous sys-
em, such as: anticonvulsant, antidepressant, analgesic, sedative
nd hypnotic effects (Faggion et al., 2011; Flausino et al., 2007a,b).
ystematic phytochemical investigations reported the occurrence
f over one hundred structural Erythrina alkaloids derivatives (Juma
nd Majinda, 2004; Wanjala et al., 2002). Biological studies regard-
ng its anxiolytic properties have supported the popular use and
he mechanism of action was described as 42 nicotinic recep-
ors antagonist. In the last decade, initial pharmaceutical products
∗ Corresponding authors.
E-mails: joaoluis@usp.br (J.L.C. Lopes), thais@lychnoﬂora.com.br (T. Guaratini).
http://dx.doi.org/10.1016/j.bjp.2015.05.011
102-695X/© 2015 Sociedade Brasileira de Farmacognosia. Published by Elsevier Editorawere commercially available, but until now there are no pharma-
cokinetics data of the active compounds and only few results about
putative metabolism have been reported (Guaratini et al., 2014;
Perdigao et al., 2013).
Metabolism of a drug candidate often decides whether it is
safe and effective for clinical application. The understanding of
speciﬁc drug metabolites is often a key for the success of drug dis-
covery (Cusack et al., 2013; Chen et al., 2014) and it is crucial to
inform several important structural properties as new pharmaco-
logically inactive or toxic entities, poor bioavailability, efﬁcacy, and
safety-related events. Therefore, such an early screening in drug
development is necessary (Fraga et al., 2011).
Rat and human liver microsomes (RLM and HLM) are mainly
employed for metabolite proﬁling purposes (Spaggiari et al., 2014;
Yuan et al., 2014). The system contains the main drug-metabolizing
enzymes, such as the cytochrome P450 (CYP450) family and ﬂavin
monooxygenase (Chen et al., 2014), Phase I and Phase II enzymes,
which can generate valuable information to predict and avoid prob-
lems during in vivo studies (Nowak et al., 2014).
In this way, our group has been dedicated to investigate Phase
I metabolites for a series of natural products (Marques et al.,
2014; Messiano et al., 2013; Moreira et al., 2013). Analysis of
erythraline (1, ERT) metabolization by pig microbiota suggests
a high stability in intestinal portion, but applying bioorganic
catalysis, one putative metabolite was formed and identiﬁed as
8-oxo-erythraline (2) (Guaratini et al., 2014). Considering ERT
(1) as a promising drug candidate, its metabolism still requires
 Ltda. All rights reserved.
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lariﬁcations. Therefore, the aim of the present work was to
nvestigate its in vitro metabolism by liver microsomes obtained
rom rats, as well as from human beings, in order to predict the
n vivo metabolism, comparing with previous related results and
o improve pre-clinical information of alkaloids from Erythrina
enus.
aterials and methods
The ERT (1) was extracted from Erythrina verna Vell., Fabaceae,
ccording to published procedures (Guaratini et al., 2014) and some
ontrol analogs were obtained as previously described (Callejon
t al., 2014). Sodium chloride and sodium dihydrogen phosphate
ere obtained from Merck (Darmstadt, Germany). Sodium hydrox-
de and potassium chloride were obtained from Nuclear (São
aulo, Brazil). Glycerol and tris-(hydroxymethyl)-aminomethane
ere obtained from J.T. Baker (Phillipsburg, NJ, USA), ethylene-
iaminetetraacetic acid (EDTA) from Carlo Erba (Milan, Italy).
ADP+, glucose-6-phosphate and glucose-6-phosphate dehydro-
enase were obtained from Sigma–Aldrich (St. Louis, MO,  USA).
Male Wistar rats weighing 180–220 g were obtained from
he School of Pharmaceutical Sciences of Ribeirão Preto, Uni-
ersity of Sao Paulo. The Ethical Committee from University
f São Paulo approved the studies. Microsomal preparation
as performed according published procedures (Marques et al.,
014). Rat liver microsome incubations (shaking water bath at
7 ◦C) were performed in 10 ml  amber tubes in a total incuba-
ion volume of 1000 l. Incubations contained 250 l cofactor
olution, 35 l rat liver microsomes (29.6 mg  ml−1 microsomal pro-
ein), 715 l phosphate buffer (pH 7.4; 0.25 mol  l−1) and 25 l
RT (1; 500 g ml−1). The cofactor solution consisted of NADP+
0.25 mmol  l−1), glucose-6-phosphate (5 mmol  l−1) and glucose-6-
hosphate dehydrogenase (0.5 units) in Tris–HCl buffer (Tris–HCl
.05 mol  l−1 – KCl 0.15 mol  l−1, pH 7.4).
Human liver microsome incubations (BD GentestTM, Woburn,
A,  EUA) were performed according Clements and Li (2011): to
void multiple freeze–thaw cycles and maintain enzyme activity
he microsomes and NADPH regenerating system were divided
nto single use fractions and stored at −94 ◦C until needed. Amber
ubes in a total incubation volume of 200 l were used. Incubations
ontained 100 l human liver microsome (4 mg  ml−1 microsomal
rotein), 100 l NADPH regenerating system (NRS) (40 l 0.5 M
hosphate buffer pH 7.4, 10 l Solution A, 2 l Solution B, both
rom BD GentestTM), 5 l ERT (1; 1.38 mg  ml−1).
After prewarming for 5 min  at 37 ◦C, the metabolic reactions
ere initiated by the addition of the rat and human liver micro-
omes, separately. To stop metabolic reaction after 90 min, it was
dded 4 ml  and 1 ml  of chloroform, respectively, to incubations with
at and human liver microsomes. Then, the sample preparation was
erformed. Control incubations were performed in the absence of
he cofactor solution and in the absence of the microsomal prepa-
ation. The difference between ‘with’ and ‘without’ NADPH was
onsidered CYP450-mediated metabolism. To perform the experi-
ents, the samples were pooled from ten single incubations.
A liquid–liquid extraction (LLE) procedure was applied to extract
he ERT (1) from the rat and human liver microsomes. After the
xtraction procedure, the samples were shaken for 15 min  (Vibrax Farmacognosia 25 (2015) 529–532
VXR agitator, IKA, Staufen, Germany) and centrifuged for 5 min
at 2860 × g (Hitachi CF16RXII, Himac, Tokyo, Japan). The super-
natant was  collected (3 ml  and 750 l, respectively, from rat and
human microsomal preparation samples) and allowed to evapo-
rate to dryness under a gentle stream of nitrogen. Then, the residue
was reconstituted in 200 l of methanol, and 1 l was  injected into
the chromatography system.
In order to investigate the formation of metabolites, the
samples were analyzed by a gas chromatograph (GC-MS-QP-
2010, Shimadzu) coupled to a quadruple mass spectrometer
with electron impact (EI) ionization at 70 eV. The gas chro-
matograph was  equipped with an auto sampler AOC-20i, 1 l
split injections 1/10 were performed at 250 ◦C. Separations were
carried out on a 5% phenyl methyl siloxane (DB-5ms) column
(30 m × 0.25 mm × 0.25 m ﬁlm thickness). The oven temperature
program for separation conditions were 100 ◦C for 0.8 min  fol-
lowed by temperature increases to 220 ◦C at 6 ◦C min−1, 220 ◦C for
10 min, temperature increases to 290 ◦C at 6 ◦C min−1, and 290 ◦C
for 11 min. The carrier gas was  ultrapure helium helium (grade 5.5)
at constant ﬂow rates of 1.10 ml min−1. A mass range of m/z  50–500
was recorded in the full-scan mode. Finally, the metabolites were
compared with authentically samples previous isolated.
To accumulate enough metabolite used for 1H NMR  analysis, rat
liver microsome incubation was  performed as previous described
to 150 individual tubes (ERT, 1, 2000 g ml−1). Then, this pool was
submitted to semipreparative LC using the following conditions:
C18 column (Shim-pack Prep-ODS, 5 m,  20 mm × 25 cm,  Shi-
madzu), ﬂow rate 9 ml  min−1 and acetonitrile (B) and H2O (A) both
with TFA 0.02% (v/v) as solvents. The elution proﬁle was 0–25 min
(15–65%, B), 25–30 min  (25–80%, B), 30–32 min  (80–100%, B) and
32–35 min  (100%, B). The isolated compound was  characterized
by NMR  (Bruker Avance® DRX-500) in a Shigemi symmetrical
susceptibility-matched microtube.
Results and discussion
Pure ERT (1) elutes in GC–MS analysis at Rt 30.6 min  (Fig. 1,
charts A and B) and no other signal was  observed. The chro-
matogram of the test reaction employing rat and human liver
microsomes presented a new peak at the same Rt 29.81 min  show-
ing that there was a correlation between both microsomal models
(Fig. 1, charts A and B). The absence of signals in the blank and con-
trol samples conﬁrm the enzymatic conversion probably thought
an oxidative reaction. The electron ionization mass spectra of the
signal 1 at Rt 29.81 show an increment of 14 mass units (Fig. 1,
chart D), related to ERT (Fig. 1, chart C). This result suggests an oxi-
dation through a carbonyl group formation as previous observed
for other natural products (Niehues et al., 2012; Santos et al., 2005,
2008). The fragmentation pattern of both compounds showed simi-
lar neutral eliminations conﬁrming the homology between the two
structures.
To conﬁrm the metabolite structure large-scale rat liver micro-
some incubation was performed as previous described (applied
150 individual tubes of ERT at 2000 g ml−1). Then, this pool was
submitted to semipreparative LC affording 900 g. After the sol-
vent elimination, the sample was  characterized by NMR  (Bruker
Avance® DRX-500) in a Shigemi symmetrical susceptibility-
matched microtube. The 1H NMR  (CDCl3, 500 MHz) spectra of the
isolated metabolite exhibited the signals (see supplementary data
associated with this article): ıH 6.33 (m,  H-1), 6.72 (s, H-14), 6.72
(s, H-17), 6.89 (m,  H-2), 6.15 (s, H-7), 5.94 (d, O-CH2-O), 5.91 (d,
O-CH2-O), 3.90 (m,  H-3), 3.78 (m,  H-10), 3.68 m (m, H-10), 3.35 (s,
OCH3), 3.15 (m,  H-11), 2.99 (m,  H-11), 2.82 (m, H-4), 2.10 (m, H-4).
The data are in agreement with 8-oxo-erythraline (2), which was
previous described by Mantle et al. (1984). Finally ESI-HRMS (pos.
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Fig. 1. Representative GC chromatograms of rat (chart A) and human microsomes extracts (chart B), signal 1: 8-oxo-erythraline (Rt = 29.81 min) and signal 2: ERT
( C (con
m r micr
E
i
[
C
m
h
t
s
a
e
c
m
l
fRt = 30.6 min). Lines T (test samples) of ERT metabolism after incubation; lines 
icrosomal preparation without ERT. Left: rat liver microsomes; right: human live
I-MS data of 8-oxo-erythraline (Rt = 29.81 min).
on mode) conﬁrmed the molecular structure (observ. m/z 312.1228
M+H]+; calcd. for C18H18NO4+ 312.1230, error = 0.6 ppm).
onclusion
This paper describes, for the ﬁrst time, the CYP450-mediated
etabolism of a promising natural product, ERT (1), using rat and
uman liver microsomes. Its metabolism showed the formation of
he previously formed 8-oxo-erythraline (2) by bioinorganic cataly-
is (Guaratini et al., 2014). This compound was previously isolated
s a minor compound in some cultivar of E. verna and biological
valuation applying macrophage and Leishmania cells revealed low
ytotoxic activity for the ERT analog alkaloids investigated. In this
anner, this compound should be considered as possible metabo-
ite in the in vivo metabolism and its toxicological effect must be
urther investigated.trol) in both microsomal preparation without NADPH cofactor; lines B (blank):
osomes. Chart C shows the EI-MS data of ERT (Rt = 30.6 min) and chart D shows the
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